Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MACK
CUSIP59032810
Phone617-441-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.45
Quick Ratio3.45
Price-To-Earnings
Trailing P/E Ratio-0.75
Forward P/E Ratio-1.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$144.27 million
Price / Sales0.39
Cash FlowN/A
Price / CashN/A
Book Value$7.22 per share
Price / Book0.59
Profitability
EPS (Most Recent Fiscal Year)($5.66)
Net Income$472.02 million
Net MarginsN/A
Return on Equity-60.33%
Return on Assets-42.77%
Miscellaneous
Employees72
Outstanding Shares13,340,000
Market Cap$53.51 million
Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions
What is Merrimack Pharmaceuticals' stock symbol?
Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?
Shares of Merrimack Pharmaceuticals reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Merrimack Pharmaceuticals' earnings last quarter?
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) released its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.28) by $0.05. View Merrimack Pharmaceuticals' Earnings History.
When is Merrimack Pharmaceuticals' next earnings date?
What price target have analysts set for MACK?
3 equities research analysts have issued 1 year price targets for Merrimack Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they anticipate Merrimack Pharmaceuticals' share price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 6.1%. View Analyst Price Targets for Merrimack Pharmaceuticals.
What is the consensus analysts' recommendation for Merrimack Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merrimack Pharmaceuticals in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merrimack Pharmaceuticals.
Who are some of Merrimack Pharmaceuticals' key competitors?
Some companies that are related to Merrimack Pharmaceuticals include Melinta Therapeutics (MLNT), Protagonist Therapeutics (PTGX), Aeglea Bio Therapeutics (AGLE), Xenon Pharmaceuticals (XENE), Galectin Therapeutics (GALT), Affimed (AFMD), Newron Pharmaceuticals (NWPHF), Calithera Biosciences (CALA), Mersana Therapeutics (MRSN), Teligent (TLGT), Galmed Pharmaceuticals (GLMD), Cerecor (CERC), Constellation Pharmaceuticals (CNST), Achaogen (AKAO) and REDHILL BIOPHAR/S (RDHL).
Who are Merrimack Pharmaceuticals' key executives?
Merrimack Pharmaceuticals' management team includes the folowing people:
- Dr. Richard Peters, Pres, CEO & Director (Age 55)
- Ms. Jean M. Franchi, CFO & Treasurer (Age 52)
- Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 41)
- Dr. Daryl C. Drummond Ph.D., Head of Research (Age 49)
- Dr. Sergio L. Santillana, Chief Medical Officer (Age 55)
Who are Merrimack Pharmaceuticals' major shareholders?
Merrimack Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Stonebridge Capital Management Inc. (0.26%). Company insiders that own Merrimack Pharmaceuticals stock include Daryl C Drummond and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals.
Which institutional investors are buying Merrimack Pharmaceuticals stock?
How do I buy shares of Merrimack Pharmaceuticals?
Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merrimack Pharmaceuticals' stock price today?
One share of MACK stock can currently be purchased for approximately $4.26.
How big of a company is Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals has a market capitalization of $53.51 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe.
What is Merrimack Pharmaceuticals' official website?
How can I contact Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]
MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
